CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

2025 Market Outlook: CLSA anticipates a challenging year for the Nifty in 2025, driven by an uncertain and risky global macro environment coupled with a near-term economic slowdown in India.

CLSA has included Zomato in its High Conviction Outperform list, maintaining an "Overweight" rating and increasing the target ...

This is the first time Indus Towers has received a ₹575 target, making it the highest among analysts covering the telecom ...

Vikash Kumar Jain, India Strategist and Head of Research at CLSA, predicts 2025 will be a year of consolidation for Indian markets. He noted that the consolidation trend, which began in October, could ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

Bank Mandiri (IDX: BMRI) is projected to become Indonesia’s most profitable bank by 2025, surpassing Bank Rakyat Indonesia ...

CLSA believes the company must reduce its dependence on the Creta and introduce higher-priced SUVs in the Rs 20 Lakh+ segment ...